News | April 22, 2022
WHO recommends Paxlovid for Covid-19 therapy
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
Researchers have developed a plasma-based disinfectant generated with the help of cold atmospheric pressure plasma (CAP) which could act as a green decontaminant for Covid-19
The MicroGEM Saliva test is the first point of care PCR saliva test for Covid-19 delivering results in minutes
The report pointed out that in the process of treating Covid-19, there are promising data to suggest that TCM is beneficial in reducing the risk of progression from mild-to-moderate cases to severe Covid-19
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Subscribe To Our Newsletter & Stay Updated
